NCT05935748 2025-11-12Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)NiKang Therapeutics, Inc.Phase 2 Terminated18 enrolled